Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer

Pancreatology

Volumn 17, Issue 5, 2017, Pages 782-787

  Sunagawa, Masaki ^a   Yamaguchi, Junpei ^a   Kokuryo, Toshio ^a   Ebata, Tomoki ^a   Yokoyama, Yukihiro ^a   Sugawara, Gen ^a   Nagino, Masato ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Invasion front; Pancreatic cancer; Prognosis; pS2; Trefoil factor family 1

Indexed keywords

TREFOIL FACTOR 1; TFF1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATECTOMY; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR INVASION; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; PANCREATIC NEOPLASMS; PROGNOSIS; TREFOIL FACTOR-1;

EID: 85026438142     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2017.07.188     Document Type: Article

References (37)

1. Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 (2014), 2913–2921.
2. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
3. Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (2007), 267–277.
4. Ueno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., et al. A randomised phase Ⅲ trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101 (2009), 908–915.
5. Lim, J.E., Chien, M.W., Earle, C.C., Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237 (2003), 74–85.
6. Strobel, O., Hinz, U., Gluth, A., Hank, T., Hackert, T., Bergmann, F., et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg 261 (2015), 961–969.
7. Ahn, D.H., Williams, T.M., Goldstein, D.A., El-Rayes, B., Bekaii-Saab, T., Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev 42 (2016), 10–17.
8. Distler, M., Aust, D., Weitz, J., Pilarsky, C., Grutzmann, R., Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int, 2014, 2014, 474905.
9. Luttges, J., Zamboni, G., Longnecker, D., Kloppel, G., The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 25 (2001), 942–948.
10. Distler, M., Kersting, S., Niedergethmann, M., Aust, D.E., Franz, M., Ruckert, F., et al. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg 258 (2013), 324–330.
11. Taupin, D., Wu, D.C., Jeon, W.K., Devaney, K., Wang, T.C., Podolsky, D.K., The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest 103 (1999), R31–R38.
12. Taupin, D., Podolsky, D.K., Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4 (2003), 721–732.
13. Yamaguchi, J., Liss, A.S., Sontheimer, A., Mino-Kenudson, M., Castillo, C.F., Warshaw, A.L., et al. Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. Stem Cell Res 15 (2015), 190–202.
14. Yamaguchi, J., Mino-Kenudson, M., Liss, A.S., Chowdhury, S., Wang, T.C., Castillo, C.F., et al. Loss of trefoil factor 2 from pancreatic duct glands promotes formation of intraductal papillary mucinous neoplasms in mice. Gastroenterology 151 (2016), 1232–1244.
15. Sagol, O., Tuna, B., Coker, A., Karademir, S., Obuz, F., Astarcioglu, H., et al. Immunohistochemical detection of PS2 protein and heat shock Protein-70 in pancreatic adenocarcinomas. Relationship with disease extent and patient survival. Pathol Res Pract 198 (2002), 77–84.
16. Terris, B., Blaveri, E., Crnogorac-Jurcevic, T., Jones, M., Missiaglia, E., Ruszniewski, P., et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160 (2002), 1745–1754.
17. Prasad, N.B., Biankin, A.V., Fukushima, N., Maitra, A., Dhara, S., Elkahloun, A.G., et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65 (2005), 1619–1626.
18. Guppy, N.J., El-Bahrawy, M.E., Kocher, H.M., Fritsch, K., Qureshi, Y.A., Poulsom, R., et al. Trefoil factor family peptides in normal and diseased human pancreas. Pancreas 41 (2012), 888–896.
19. Kornprat, P., Rehak, P., Lemmerer, M., Gogg-Kamerer, M., Langner, C., Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma. Virchows Arch 446 (2005), 505–510.
20. Corte, M.D., Tamargo, F., Alvarez, A., Rodriguez, J.C., Vazquez, J., Sanchez, R., et al. Cytosolic levels of TFF1/pS2 in breast cancer: their relationship with clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat 96 (2006), 63–72.
21. Tanaka, T., Nakamura, J., Kitajima, Y., Kai, K., Miyake, S., Hiraki, M., et al. Loss of trefoil factor 1 is regulated by DNA methylation and is an independent predictive factor for poor survival in advanced gastric cancer. Int J Oncol 42 (2013), 894–902.
22. Zhao, S., Ma, Y., Huang, X., Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling. Int J Clin Exp Pathol 8 (2015), 10412–10419.
23. Perry, J.K., Kannan, N., Grandison, P.M., Mitchell, M.D., Lobie, P.E., Are trefoil factors oncogenic?. Trends Endocrinol Metab 19 (2008), 74–81.
24. Arumugam, T., Brandt, W., Ramachandran, V., Moore, T.T., Wang, H., May, F.E., et al. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas 40 (2011), 815–822.
25. Sobin, L.H., Gospodarowicz, M.K., Wittekind, C., International union against cancer., ebrary Inc.: TNM classification of malignant tumours. seventh ed., 2009, Wiley-Blackwell, UK; Hoboken, NJ Chichester, West Sussex.
26. Morris, JPt, Wang, S.C., Hebrok, M., KRAS, Hedgehog, wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10 (2010), 683–695.
27. Waddell, N., Pajic, M., Patch, A.M., Chang, D.K., Kassahn, K.S., Bailey, P., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518 (2015), 495–501.
28. Masiakowski, P., Breathnach, R., Bloch, J., Gannon, F., Krust, A., Chambon, P., Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10 (1982), 7895–7903.
29. Henry, J.A., Bennett, M.K., Piggott, N.H., Levett, D.L., May, F.E., Westley, B.R., Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 64 (1991), 677–682.
30. Collier, J.D., Bennett, M.K., Bassendine, M.F., Lendrum, R., Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. J Gastroenterol Hepatol 10 (1995), 396–400.
31. Radiloff, D.R., Wakeman, T.P., Feng, J., Schilling, S., Seto, E., Wang, X.F., Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process. Proc Natl Acad Sci U. S. A 108 (2011), 6591–6596.
32. De Wever, O., Pauwels, P., De Craene, B., Sabbah, M., Emami, S., Redeuilh, G., et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 130 (2008), 481–494.
33. Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U. S. A 98 (2001), 10356–10361.
34. INK4A and is a region of low proliferation. Am J Pathol 159 (2001), 1613–1617.
35. Suarez, C., Vizoso, F., Rodriguez, J.C., Garcia, I., Raigoso, P., Allende, M.T., et al. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int J Biol Markers 16 (2001), 37–44.
36. Sonoda, H., Yamamoto, K., Kushima, R., Yamamoto, H., Naitoh, H., Okabe, H., et al. Detection of lymph node micrometastasis in pN0 early gastric cancer: efficacy of duplex RT-PCR with MUC2 and TFF1 in mucosal cancer. Oncol Rep 16 (2006), 411–416.
37. Yang, J., Weinberg, R.A., Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14 (2008), 818–829.